Leukaemia gene provides clue to treating triple negative breast cancer

June 27, 2014, Cancer Research UK

(Medical Xpress)—Cancer Research UK scientists have discovered that a gene previously linked to leukaemia could provide an urgently needed target for the development of drugs to treat patients with 'triple negative' breast cancer, according to a study published in PLOS ONE, today (Thursday).

The team of researchers at the Cancer Research UK Beatson Institute and University of Glasgow, measured levels of a protein produced by the RUNX1 gene in tumour samples from 483 patients with a range of types*.

They found that patients with triple negative breast cancer who had the RUNX1 protein in their cells had poorer survival compared to those without the RUNX1 protein.

Of the 118 patients with , those who tested positive for the RUNX1 protein were around four times more likely to die from their cancer in the follow-up period – around 14 years on average – than those without it.

And the faulty gene could provide a target for the development of new drugs to treat the disease as well.

Every year between 4,800 and 16,100 women are diagnosed with triple negative breast cancer in the UK**.

The disease is often hard to treat as the cancer cells do not contain receptors for the hormones oestrogen or progesterone – targeted by hormone therapies such as tamoxifen – or receptors for the protein HER2, treatable with Herceptin.

RUNX1 plays an important role in controlling cell development and is one of the most commonly altered genes in leukaemia. But this is the first time it has been implicated in triple negative breast cancer.

Study author, Dr Karen Blyth, at the Cancer Research UK Beatson Institute and University of Glasgow, said: "Because levels of RUNX1 appear to be linked to triple negative breast cancers, this opens up the exciting possibility of using it as a new target for treatments.

"Now we've got to prove this early research in larger studies and pin down exactly what's happening in these cells, to understand how this protein behaves in tumours."

Dr Kat Arney, Cancer Research UK's science communications manager, said: "There's still so much we need to understand about triple negative breast cancers, as they can be harder to treat in some people.

"Almost two out of three women with breast cancer now survive their disease beyond 20 years. But more must be done and we urgently need more studies like these, particularly in lesser-understood forms of the disease, to build on the progress we've already made and save more lives."

Explore further: Scientists find promising new target for aggressive breast cancer

More information: Ferrari N, Mohammed ZMA, Nixon C, Mason SM, Mallon E, et al. (2014) "Expression of RUNX1 Correlates with Poor Patient Prognosis in Triple Negative Breast Cancer." PLoS ONE 9(6): e100759. DOI: 10.1371/journal.pone.0100759

Related Stories

Scientists find promising new target for aggressive breast cancer

March 20, 2013
Women with triple-negative breast cancer are more likely to have high levels of the MET biomarker in their tumours, making it a good new target for cancer drugs according to research published in the British Journal of Cancer, ...

Triple negative breast cancer, ethnicity, and socioeconomic status

May 12, 2014
An analysis of a large nationwide dataset finds that regardless of their socioeconomic status, black women were nearly twice as likely as white women to be diagnosed with triple-negative (TN) breast cancer, a subtype that ...

Virus kills triple negative breast cancer cells, tumor cells in mice

June 24, 2014
A virus not known to cause disease kills triple-negative breast cancer cells and killed tumors grown from these cells in mice, according to Penn State College of Medicine researchers. Understanding how the virus kills cancer ...

Seven new markers discovered for hard-to-treat breast cancer

October 25, 2013
(Medical Xpress)—Pioneering research from Breakthrough Breast Cancer scientists has discovered seven molecular markers that contribute to the behaviour of triple negative breast cancers, revealing new insight into this ...

New way to predict response to chemo in triple-negative breast cancer

May 14, 2014
Researchers from University Hospitals (UH) Case Medical Center's Seidman Cancer Center will present findings from a study that found the presence of tumor-infiltrating lymphocytes, a type of white blood cell, ahead of treatment ...

New finding points to potential options for attacking stem cells in triple-negative breast cancer

February 17, 2014
New research from the University of Michigan Comprehensive Cancer Center and Georgia Regents University finds that a protein that fuels an inflammatory pathway does not turn off in breast cancer, resulting in an increase ...

Recommended for you

T-cells engineered to outsmart tumors induce clinical responses in relapsed Hodgkin lymphoma

January 16, 2018
WASHINGTON-(Jan. 16, 2018)-Tumors have come up with ingenious strategies that enable them to evade detection and destruction by the immune system. So, a research team that includes Children's National Health System clinician-researchers ...

Researchers identify new treatment target for melanoma

January 16, 2018
Researchers in the Perelman School of Medicine at the University of Pennsylvania have identified a new therapeutic target for the treatment of melanoma. For decades, research has associated female sex and a history of previous ...

More evidence of link between severe gum disease and cancer risk

January 16, 2018
Data collected during a long-term health study provides additional evidence for a link between increased risk of cancer in individuals with advanced gum disease, according to a new collaborative study led by epidemiologists ...

Researchers develop a remote-controlled cancer immunotherapy system

January 15, 2018
A team of researchers has developed an ultrasound-based system that can non-invasively and remotely control genetic processes in live immune T cells so that they recognize and kill cancer cells.

Dietary fat, changes in fat metabolism may promote prostate cancer metastasis

January 15, 2018
Prostate tumors tend to be what scientists call "indolent" - so slow-growing and self-contained that many affected men die with prostate cancer, not of it. But for the percentage of men whose prostate tumors metastasize, ...

Pancreatic tumors may require a one-two-three punch

January 15, 2018
One of the many difficult things about pancreatic cancer is that tumors are resistant to most treatments because of their unique density and cell composition. However, in a new Wilmot Cancer Institute study, scientists discovered ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.